Is ondansetron (Zofran) safe for use during pregnancy?

Ondansetron Safety in Pregnancy

Ondansetron can be used safely during pregnancy, but should be used with caution before 10 weeks gestation due to small absolute increases in cardiac septal defects (0.3%) and cleft palate (0.03%), making it a second-line agent after metoclopramide and vitamin B6-based therapies. 1

Treatment Algorithm for Nausea in Pregnancy

First-Line Therapy

• Start with vitamin B6 (pyridoxine) 10-25 mg orally every 8 hours for mild nausea and vomiting of pregnancy 1
• If inadequate response, escalate to doxylamine-pyridoxine combination (Diclectin) as the preferred first-line pharmacologic therapy 1

Second-Line Therapy

• Metoclopramide 5-10 mg orally every 6-8 hours (3-4 times daily) is the preferred second-line agent, with a meta-analysis of 33,000 first-trimester exposures showing no increased risk of major congenital defects (OR 1.14,99% CI 0.93-1.38) 1, 2
• Promethazine is an alternative second-line option with comparable efficacy but more side effects than metoclopramide 1

Third-Line Therapy: Ondansetron

• Ondansetron 8 mg orally every 8-12 hours should be reserved for severe symptoms or when first- and second-line therapies fail 1
• Before 10 weeks gestation: Use ondansetron only on a case-by-case basis when benefits outweigh risks, as ACOG recommends individualized decision-making during this critical period 1, 3
• After 10 weeks gestation: Ondansetron can be used more liberally, as the risk window for cardiac and orofacial malformations has largely passed 1

Quantified Risk Assessment for Ondansetron

Cardiac Malformations

• Ventricular septal defects increase from baseline to 0.3% absolute increase when ondansetron is used in the first trimester 1
• A meta-analysis found an association with VSD (OR 1.11,95% CI 1.00-1.23) 4

Orofacial Clefts

• Cleft palate risk increases from 11 per 10,000 births to 14 per 10,000 births (0.03% absolute increase) 1
• Meta-analysis showed increased risk of oral clefts (OR 1.22,95% CI 1.00-1.49) and cleft palate specifically (OR 1.48,95% CI 1.19-1.84) 4

Reassuring Safety Data

• No increased risk of spontaneous abortion, stillbirth, or overall major congenital malformations in multiple large cohort studies 5, 6, 7
• The FDA label confirms that published epidemiological studies show inconsistent findings with important methodological limitations, but available data have not identified increased risk of miscarriage or adverse maternal outcomes 8
• A Danish cohort of 608,385 pregnancies found no association with spontaneous abortion, stillbirth, preterm delivery, or low birth weight 6

Critical Clinical Caveats

Timing Matters Most

• The critical window for cardiac and orofacial malformations is before 10 weeks gestation (palate forms between weeks 6-9) 1, 8
• After 10 weeks, ondansetron's safety profile improves substantially, making it a more reasonable option for persistent symptoms 1

Comparative Safety

• Metoclopramide has a cleaner safety profile throughout pregnancy with no association with congenital defects in 33,000 first-trimester exposures, making it the preferred antiemetic before ondansetron 1, 2
• Metoclopramide has similar efficacy to promethazine but fewer side effects (less drowsiness, dizziness, dystonia) 1, 2

When to Use Ondansetron Despite Risks

• Severe hyperemesis gravidarum requiring hospitalization where benefits clearly outweigh small absolute risks 1, 3
• After failure of metoclopramide and other first-line agents, particularly after 10 weeks gestation 1
• In oncology patients receiving chemotherapy during pregnancy, where ESMO and NCCN support ondansetron use even in the first trimester when managing severe chemotherapy-induced nausea 1

Practical Prescribing Guidance

• Avoid ondansetron as first-line therapy—always try vitamin B6 ± doxylamine and metoclopramide first 1
• Document shared decision-making when prescribing ondansetron before 10 weeks, discussing the 0.3% cardiac and 0.03% cleft palate absolute risk increases 1
• Consider IV ondansetron 0.15 mg/kg (max 16 mg) over 15 minutes for hospitalized patients with severe symptoms when oral therapy fails 1
• Monitor for extrapyramidal symptoms with metoclopramide and discontinue immediately if they develop (more common in patients <30 years old) 2